RCT of Tri-Modalities with I-125 Brachy Therapy and EBRT and Short or Long Term Hormone Therapy for High-risk Localized Prostate Cancer
- Conditions
- Prostate Cancer
- Registration Number
- JPRN-UMIN000003992
- Lead Sponsor
- Kanazawa University Translational Research Informatices Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- Male
- Target Recruitment
- 340
Not provided
1) Patients who have active double cancer 2) Patients with poorly controlled hypertension (i.e., diastolic blood pressure>=120 mm Hg) 3) Patients with severe psychiatric disorders 4) Patients with collagen diseases 5) Patients with poorly controlled diabetes 6) Patients with poorly controlled ischemic cardiac disease 7) Patients who had prior surgery for prostate (transurethral prostatectomy, radical prostatectomy, orchiectomy, other surgery for BPH and/or hyperthermia) 8) Patients who had brachytherapy and/or EBRT 9) Patients who are taking steroid drugs (except for ointment) 10) Patients who are taking other antiandrogen for BPH 11) Patients who had CAB for more than 3 months prior to the registration 12) Patients who are judged inappropriate for the clinical trial by doctors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Biochemical progression free survival (PSA progression free survival)
- Secondary Outcome Measures
Name Time Method 1.Overall survival 2.Clinical progression free survival 3.Cause specific survival 4.Time to salvage therapy 5.QOL 6.Adverse Events